Introduction {#s0005}
============

Cells of the monocyte/macrophage lineage are considered key components of the tumor microenvironment that operate in conflicting ways as tumor-antagonizing or tumor-promoting inflammatory cells [@bb0005; @bb0010]. Thus, tumor-associated macrophages (TAMs) are characterized by their diversity and plasticity, which can undergo two polarization states that represent extremes of a continuum: the classically activated M1 (proinflammatory) and the alternatively activated M2-like (tumor promoting) phenotypes [@bb0015]. Studies of several types of human solid tumors, including gliomas, have resulted in controversial findings regarding the correlation of the presence of TAMs and prognosis [@bb0020; @bb0025; @bb0030; @bb0035]. Functional studies aiming to deplete macrophages in glioma animal models have not explained these discrepancies and described macrophages as having either a positive or a negative influence on tumor growth [@bb0040; @bb0045].

Modeling the tumor microenvironment is one of the most challenging areas of research due to the paucity of models for studying its inherent complexity. In this work, we took advantage of a previously generated transgenic model that allows conditional and temporal ablation of the macrophage population [@bb0050]. The macrophage Fas-induced apoptosis (MAFIA) transgenic mouse model has been previously validated in studies on the role of macrophages in bone marrow homeostasis [@bb0055; @bb0060; @bb0065] and in several pathogenic diseases [@bb0070; @bb0075]. In this model, a murine *c-fms* promoter induces the expression of a transgene containing enhanced green fluorescent protein (EGFP) and a suicide fusion protein made up of the FK506-binding protein and the cytoplasmic domain of Fas. Expressed on cells of the mononuclear phagocyte system in the mouse, *c-fms* encodes the receptor for macrophage colony-stimulating factor (CSF-1) [@bb0080]. CSF-1R is known to be expressed in monocytes, tissue macrophages, and monocyte-derived dendritic cells [@bb0085]. Specifically, in the MAFIA brain tissue, EGFP is detectable in macrophages associated with the microvasculature and meningeal surfaces and in microglia [@bb0080]. Systemic administration of AP20187 dimerizes the suicide protein, inducing Fas-mediated apoptosis through activation of the caspase-8 pathway in myeloid lineage cells (i.e., macrophages and dendritic cells) and ultimately reducing the number of EGFP^+^ cells by more than 90% in bone marrow and peritoneum and more than 70% in blood and in spleen, lung, and thymus tissue [@bb0050]. The use of this model in cancer has so far been limited to two recent studies on metastasis of B16-F10 melanoma [@bb0090] and in combination with a preneoplastic progression model for breast cancer [@bb0095].

In this study, we analyzed the kinetics of intracranial syngeneic murine GL261 cells by using the MAFIA mouse model to allow for easy identification and conditional ablation of the tumor-associated myeloid population. Our study unequivocally demonstrated the role of CSFR-1R^+^ myeloid population in tumor proliferation, angiogenesis, and growth at different stages of tumor development. In addition, we show a switch in the M2/M1 polarization status that accompanies the repopulation of TAMs on conditional myeloid ablation. Finally, the work presented here sets up the basis for further studies on the pathobiology of macrophages and drug testing for malignant glioma treatments.

Materials and Methods {#s0010}
=====================

Cell Culture and *In Vitro* Studies {#s0015}
-----------------------------------

Murine GL261 glioma cells and the RAW 264.7 macrophage cell line were obtained from the Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD) Tumor Repository (National Institutes of Health (NIH), Frederick, MD) and American Type Culture Collection (ATCC), Manassas, Virginia, respectively, and cultured in Dulbecco's modified Eagle's medium (Cellgro) with 10% FBS (Cellgro) and antibiotics (50 U/ml penicillin and 50 μg/ml streptomycin) in a humidified atmosphere of CO~2~/air (5%/95%) at 37°C.

For macrophage polarization, RAW 264.7 cells were cultured in complete medium and stimulated for 24 hours with 1 ng/ml lipopolysaccharides from *Escherichia coli* 055:B5 (Sigma, St. Louis, Missouri) and 10 IU/ml Interferon gamma (IFN-γ) (Peprotech, Rocky Hill, New Jersey) for M1 or 20 ng/ml Interleukin 4 (IL-4) (R&D Systems, Minneapolis, Minnesota) for M2 activation.

GL261 and RAW 264.7 cell lines were treated with AP20187 with different concentrations (0.01, 0.1, 1, and 10 nM) or vehicle for 24 or 48 hours, and cell proliferation was measured using CyQUANT Direct Cell Proliferation Assay Kit (Life Technologies, Grand Island, New York) according the manufacturer's protocol.

Real-Time Polymerase Chain Reaction Array {#s0020}
-----------------------------------------

Total RNA was extracted from RAW 264.7 and M1- and M2-skewed RAW 264.7 cells using mirVana miRNA Isolation Kit (Life Technologies). RNA (2 μg) was converted into cDNA using the High Capacity RNA-to-cDNA Kit (Life Technologies), according to the manufacturer's instructions. The TaqMan Gene Expression Assay for murine *arg1* (Mm00475988_m1), *nos2* (Mm00440502_m1), and *gapdh* (Mm99999915_g1) were purchased from Life Technologies. Quantitative polymerase chain reaction (PCR) analysis was performed using the Applied Biosystems 7500 Fast Real-Time PCR machine. Relative mRNA levels were quantified using the comparative cycle threshold (*C*~t~) method and the formula $2^{- \Delta\Delta C_{t}}$, with *gapdh* expression as the reference.

Flow Cytometry {#s0025}
--------------

Cells were washed with phosphate-buffered saline and incubated with rat anti-mouse FCγIII/II receptor (CD16/CD32; clone 2.4G2; BD Pharmingen, San Jose, California) antibody followed by APC anti-mouse CD115/cFMS/CSF-1R antibody or matched IgG control (Biolegend, San Diego, California). Before acquisition, cells were stained with propidium iodide for gating of live cells. Analysis was performed on 100,000 events collected per sample on Gallios (Beckman Coulter, Brea, California) flow cytometer and analyzed using FlowJo (Tree Star, Ashland, Oregon).

MAFIA Transgenic Mice {#s0030}
---------------------

MAFIA transgenic mice (C57BL/6-Tg(Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6)2Bck/J) were purchased from The Jackson Laboratory, Bar Harbor, Maine. Offspring were screened by PCR on tail-snip DNA taken at weaning using the Kapa Biosystems mouse genotyping kit, as per the manufacturer's instructions. GFP primers used for the analysis were 5′-AAGTTCATCTGCACCACCG-3′ (forward) and 5′-TCCTTGAAGAAGATGGTGCG-3′ (reverse). PCR thermal conditions were set up according to the protocol provided by The Jackson Laboratory.

Animal Studies {#s0035}
--------------

GL261 glioma cells (2 × 10^4^) were implanted (day 0 of the experiment) in the right caudate nucleus of MAFIA mice using a cannulated guide screw system as previously described [@bb0100], which had been placed 14 days before. The B/B homodimerizer AP20187 was purchased from Clontech Laboratories, Mountain View, California. Lyophilized AP20187 was dissolved in 100% ethanol at a concentration of 62.5 mg/ml and stored at − 20°C. For *in vivo* experiments, treatment solutions were freshly prepared from a dilution of 1.25 mg/ml (as recommended by Clontech Laboratories) consisting of 4% ethanol, 10% PEG-400 (Sigma), and 2% Tween-20 (Fisher Scientific, Pittsburgh, Pennsylvania) in water. The volume of solution was adjusted according to mouse body weight to deliver 5 mg/kg per mouse. AP20187 was injected intraperitoneally daily for 5 days, starting from either the first or the sixth day after glioma implantation. Control animals were treated with vehicle solution alone. Animals were sacrificed when indicated or when exhibiting generalized or local symptoms of disease. Brains were removed, photographed using a digital camera Nikon D60, fixed in 4% formaldehyde for 24 hours at room temperature, and embedded in paraffin. All animal studies were performed in the veterinary facilities of The University of Texas MD Anderson Cancer Center (Houston, TX) in accordance with institutional guidelines. The largest (*a*) and the smallest (*b*) diameters of the tumors were measured, and tumor volume was calculated using the formula: *a* × *b*^2^ × 0.4 [@bb0105].

Immunohistochemical and Immunofluorescence Analyses {#s0040}
---------------------------------------------------

Paraffin-embedded 5-μm-thick tissue sections were deparaffinized and subjected to graded rehydration before staining. For double immunofluorescence studies \[Arginase 1 (Arg1)/GFP, inducible nitric oxide (iNOS)/GFP, Iba1/GFP, CSF-1R/GFP\], tissue sections were subjected to heat-induced epitope retrieval (10 mM citrate buffer, pH 6.0) and blocked with 10% serum. Endogenous biotin and streptavidin were blocked using Vector avidin/biotin and streptavidin/biotin kits according to the manufacturer's instructions. Overnight incubation at 4°C with antibodies against Arg1 V-20 (sc-18354; 1:1000; Santa Cruz Biotechnology, Dallas, Texas), iNOS (ab15323; 1:1000; Abcam, Cambridge, Massachusetts), Iba1 (MABN92; 1:1000; Millipore, Billerica, Massachusetts), or CD31 antibody (AF3628, diluted 1:200, R&D Systems) was performed. Bound antibodies were detected by incubation with biotin-conjugated secondary antibody and DyLight 549 or DyLight 488 streptavidin (1:1000; Vector Laboratories, Burlingame, California). Second primary antibodies \[GFP (NB600-308; 1:500; Novus Biologicals, Littleton, Colorado), GFP I-16 (sc-5385; 1:100; Santa Cruz Biotechnology), and CSF-1R/cFMS (sc-692; 1:200; Santa Cruz Biotechnology)\] were incubated overnight at 4°C and developed with Alexa Fluor 488-- or Alexa Fluor 594--conjugated secondary antibodies (1:1000; Invitrogen, Grand Island, New York). Fluorescence-labeled slides were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Sigma), mounted with fluorescence mounting medium (Dako, Carpinteria, California), and examined under a Zeiss Axiovert 200 M fluorescence microscope or a confocal microscope (Olympus Fluoview FV1000).

For Ki67 immunohistochemical analysis, endogenous peroxidase activity was quenched with 0.3% H~2~O~2~. Sections were blocked with 10% horse serum and a Vector avidin/biotin kit. Incubation with Ki67 MM1 antibody (VP-K452; 1:100; Vector Laboratories) was performed overnight at 4°C. Sections were then incubated with biotinylated secondary antibody followed by peroxidase-conjugated streptavidin (1:500; Beckman Coulter). The reaction was developed using stable 3,3′-diaminobenzidine (DAB, Research Genetics, Huntsville, Alabama). After immunoreaction, sections were counterstained with Harris hematoxylin and mounted with Cytoseal 60 (Thermo Scientific, Waltham, Massachusetts). Images were captured using a bright-field microscope (Zeiss Axioskop 40).

For immunofluorescence and immunohistochemical analysis, 10 pictures were acquired randomly from central or peripheral areas of tumors and, when indicated, from contralateral cerebral hemispheres under × 20 or × 40 objectives. A minimum of three animals from each experimental group was analyzed. The number of GFP^+^, Ki67^+^, Arg1^+^/GFP^+^, and iNOS^+^/GFP^+^ cells was quantified in a double-blind manner by two different researchers.

Quantification of Microvessel Density {#s0045}
-------------------------------------

Areas containing the most microvessels (or tumor "hot spots") were identified following immunostaining with anti-CD31 antibody. Sections were examined with a fluorescence microscope at low magnification (original magnification, × 40 and × 100), as previously described [@bb0110]. Then, the individually stained microvessels in these areas were counted at × 200 magnification over a square grid that corresponded to a field size of 0.16 mm^2^. Large microvessels and single endothelial cells that were clearly separate from the microvessels were included in the microvessel count; branching structures were counted as one vessel, unless there was a break in the continuity of the vessel, in which case it was counted as two distinct vessels. The mean number of microvessels counted in five fields was used for analyses.

Statistical Analysis {#s0050}
--------------------

Data are presented as mean ± SD. The *P* value for difference between samples was calculated using double-sided Student's *t* test. *P* \< .05 was considered statistically significant.

Results {#s0055}
=======

Kinetics of GL261 Glioma Intracranial Growth and Tumor-Associated Microglia/Macrophage Population in MAFIA Transgenic Mice {#s0060}
--------------------------------------------------------------------------------------------------------------------------

To determine the kinetics of GL261 glioma growth in MAFIA transgenic mice, we first analyzed tumor morphologic characteristics on days 5, 10, 14, and 19 after tumor cell implantation ([Figure 1](#f0025){ref-type="fig"}*A*). We performed hematoxylin and eosin (H&E) and Ki67 staining to assist in the analysis of tumor morphology and tumor growth ([Figure 1](#f0025){ref-type="fig"}*B*). On days 5 and 10 after tumor cell inoculation, GL261-derived tumors exhibited multifocal distribution of Ki67^+^ cells in the area of injection of the brain parenchyma. On day 14, the tumors were clearly established and highly proliferative, with exponential growth. By day 19, the tumor occupied almost the entire left hemisphere with slightly less cell density that was due probably to the presence of dilated vascular structures. At that time point, examination of the brain itself revealed secondary effects to tumor mass pressure, such as midline shift and ventricular compression. The tumor/normal brain edge was well defined, and no significant signs of invasiveness were observed.

To identify the presence of tumor-associated microglia/macrophages in MAFIA mice, we performed GFP immunofluorescence staining. As early as 5 days after GL261 implantation, compared to the presence of GFP^+^ cells in contralateral, non-tumor containing hemispheres, the presence of GFP^+^ cells had increased ([Figure 2](#f0030){ref-type="fig"}*A*), which was suggestive of activation/infiltration of myeloid cells into the tumor. Thus, in tumor-free hemispheres, we detected relatively few microglia in the resting stage, with thin branching processes, and small cell bodies ([Figure 2](#f0030){ref-type="fig"}*A*). GL261-derived tumors analyzed 10 days after cell implantation displayed microglia/macrophages with morphology compatible with activation as demonstrated by their augmented cell body size and amoeboid morphology. The density of GFP^+^ cells within the tumor continued to increase, and by day 14 post-implantation, the tumors harbored an even greater number of glioma-infiltrating microglia/macrophages. Interestingly, the density of these GFP^+^ cells decreased significantly from day 14 to day 19 (*P* \< .001), associated to a decreased cellularity due to the presence of necrotic areas as previously reported [@bb0115], whereas the number of GFP^+^ cells (i.e., microglia/macrophages) at the tumor periphery increased (*P* \< .05; [Figure 2](#f0030){ref-type="fig"}, *B* and *C*). In sham-operated animals analyzed 5 and 10 days after mock implantation ([Figure W1](#f0005){ref-type="fig"}*A*), we did not observe accumulation of GFP^+^ cells in the injection area, indicating that the recruitment or activation of microglia/macrophages into the tumor was initiated by the presence of glioma cells ([Figure W1](#f0005){ref-type="fig"}*B*).

To identify the presence of tumor-associated microglia/macrophages in MAFIA mice, we performed GFP immunofluorescence staining. As early as 5 days after GL261 implantation, compared to the presence of GFP^+^ cells in contralateral, non-tumor containing hemispheres, the presence of GFP^+^ cells had increased ([Figure 2](#f0030){ref-type="fig"}*A*), which was suggestive of activation/infiltration of myeloid cells into the tumor. Thus, in tumor-free hemispheres, we detected relatively few microglia in the resting stage, with thin branching processes, and small cell bodies ([Figure 2](#f0030){ref-type="fig"}*A*). GL261-derived tumors analyzed 10 days after cell implantation displayed microglia/macrophages with morphology compatible with activation as demonstrated by their augmented cell body size and amoeboid morphology. The density of GFP^+^ cells within the tumor continued to increase, and by day 14 post-implantation, the tumors harbored an even greater number of glioma-infiltrating microglia/macrophages. Interestingly, the density of these GFP^+^ cells decreased significantly from day 14 to day 19 (*P* \< .001), associated to a decreased cellularity due to the presence of necrotic areas as previously reported [@bb0115], whereas the number of GFP^+^ cells (i.e., microglia/macrophages) at the tumor periphery increased (*P* \< .05; [Figure 2](#f0030){ref-type="fig"}, *B* and *C*). In sham-operated animals analyzed 5 and 10 days after mock implantation (Figure W1*A*), we did not observe accumulation of GFP^+^ cells in the injection area, indicating that the recruitment or activation of microglia/macrophages into the tumor was initiated by the presence of glioma cells (Figure W1*B*).

To characterize the GFP^+^ population in the MAFIA model, we analyzed the expression of Iba1 (which is highly expressed in cells of the monocyte/macrophage lineage), and CSF-1R, by double immunofluorescence. As expected, GFP and CSF-1R expression was co-localized in tumor and intact brain ([Figure W2](#f0010){ref-type="fig"}*A*). Our data show that, within the tumoral area, most Iba1^+^ cells (microglial) are GFP^+^ (82.1 ± 1.46%). Of note, in normal brain, all Iba1^+^ cells were GFP^+^ ([Figure W2](#f0010){ref-type="fig"}*B*). These data indicate that CSF-1R--expressing cells encompass an important population, although not all monocyte/macrophage lineage cells present in the glioma-bearing brain were Iba1^+^, as previously found in other organs of this transgenic model using F4/80 as a macrophage marker [@bb0050].

To characterize the GFP^+^ population in the MAFIA model, we analyzed the expression of Iba1 (which is highly expressed in cells of the monocyte/macrophage lineage), and CSF-1R, by double immunofluorescence. As expected, GFP and CSF-1R expression was co-localized in tumor and intact brain (Figure W2*A*). Our data show that, within the tumoral area, most Iba1^+^ cells (microglial) are GFP^+^ (82.1 ± 1.46%). Of note, in normal brain, all Iba1^+^ cells were GFP^+^ (Figure W2*B*). These data indicate that CSF-1R--expressing cells encompass an important population, although not all monocyte/macrophage lineage cells present in the glioma-bearing brain were Iba1^+^, as previously found in other organs of this transgenic model using F4/80 as a macrophage marker [@bb0050].

To further characterize the phenotype of the tumor-associated microglia/macrophages, we analyze the expression of Arg1 (an M2 phenotype marker) and iNOS (an M1 phenotype marker) [@bb0120; @bb0125; @bb0130]. To this end, we performed double immunofluorescence staining for GFP/Arg1 and GFP/iNOS expression in sections of brains of GL261-bearing mice sacrificed at different times after cell implantation. No Arg1^+^ cells were detected at day 5, but we observed the presence of double-positive (GFP^+^/Arg1^+^) cells at day 10, which exhibited a more rounded morphology and cellular processes compatible with early stages of microglia activation. Quantification of the Arg1^+^/GFP^+^ cells at 14 and 19 days after GL261cell implantation showed that 98 ± 1.5% of Arg1^+^ cells expressed the GFP antigen, suggesting that Arg1 is expressed by microglia/macrophages, and those exhibited an amoeboid morphology suggestive of an activate cellular stage. In addition, we observed that 50% to 75% of GFP^+^ cells expressed Arg1 and that the number of M2-polarized microglia/macrophages at the tumor-normal brain edge tended to increase during glioma growth ([Figure 3](#f0035){ref-type="fig"}, *A* and *B*). In contrast, we did not detect iNOS^+^ cells in early stages of glioma growth (days 5 and 10; [Figure 3](#f0035){ref-type="fig"}*C*) or in tumor-normal edges at later stages of tumor development. In fact, we identified very few iNOS^+^ cells expressing GFP in central tumor areas at late stages of tumor development (days 14 and 19; [Figure 3](#f0035){ref-type="fig"}*C*). These findings suggest that M2-polarized glioma-associated macrophages constitute the predominant population in GL261-derived intracranial gliomas. Of interest, most of the Arg1^+^ cells expressed GFP and approximately 70% of iNOS-positive cells in the whole tumor area expressed the fluorescent protein (72 ± 12.8%). These data suggest that M2-polarized macrophages constitute the major CSF-1R^+^ population, in agreement with our *in vitro* polarization studies ([Figure W3](#f0015){ref-type="fig"}) and a recent report that examined human macrophages [@bb0135].

To further characterize the phenotype of the tumor-associated microglia/macrophages, we analyze the expression of Arg1 (an M2 phenotype marker) and iNOS (an M1 phenotype marker) [@bb0120; @bb0125; @bb0130]. To this end, we performed double immunofluorescence staining for GFP/Arg1 and GFP/iNOS expression in sections of brains of GL261-bearing mice sacrificed at different times after cell implantation. No Arg1^+^ cells were detected at day 5, but we observed the presence of double-positive (GFP^+^/Arg1^+^) cells at day 10, which exhibited a more rounded morphology and cellular processes compatible with early stages of microglia activation. Quantification of the Arg1^+^/GFP^+^ cells at 14 and 19 days after GL261cell implantation showed that 98 ± 1.5% of Arg1^+^ cells expressed the GFP antigen, suggesting that Arg1 is expressed by microglia/macrophages, and those exhibited an amoeboid morphology suggestive of an activate cellular stage. In addition, we observed that 50% to 75% of GFP^+^ cells expressed Arg1 and that the number of M2-polarized microglia/macrophages at the tumor-normal brain edge tended to increase during glioma growth ([Figure 3](#f0035){ref-type="fig"}, *A* and *B*). In contrast, we did not detect iNOS^+^ cells in early stages of glioma growth (days 5 and 10; [Figure 3](#f0035){ref-type="fig"}*C*) or in tumor-normal edges at later stages of tumor development. In fact, we identified very few iNOS^+^ cells expressing GFP in central tumor areas at late stages of tumor development (days 14 and 19; [Figure 3](#f0035){ref-type="fig"}*C*). These findings suggest that M2-polarized glioma-associated macrophages constitute the predominant population in GL261-derived intracranial gliomas. Of interest, most of the Arg1^+^ cells expressed GFP and approximately 70% of iNOS-positive cells in the whole tumor area expressed the fluorescent protein (72 ± 12.8%). These data suggest that M2-polarized macrophages constitute the major CSF-1R^+^ population, in agreement with our *in vitro* polarization studies (Figure W3) and a recent report that examined human macrophages [@bb0135].

Ablation of Macrophages in the MAFIA Model Impairs Inflow of Myeloid Cells into the Tumor and Promotes Skew Toward the M1 Phenotype {#s0065}
-----------------------------------------------------------------------------------------------------------------------------------

To understand the role of microglia/macrophages in glioma development, we targeted this population by administering for five consecutive days (1-5 days or 6-10 days) after cell implantation the B/B homodimerizer drug AP20187 to mice bearing GL261 intracranial tumors ([Figure W4](#f0020){ref-type="fig"}*A*). As mentioned previously, AP20187 induces Fas-mediated apoptosis through activation of the caspase-8 pathway in myeloid lineage cells. The day after treatment was completed (day 6 for group A and day 11 for group B), brains were analyzed for GFP^+^ cells. In tumor-containing hemispheres, the GFP^+^ cells were forcefully depleted ([Figure W4](#f0020){ref-type="fig"}*B*). The presence of GFP^+^ cells in the contralateral, non--tumor-containing hemisphere was not affected by the treatment (data not shown). Our data suggested that normal microglia is not targeted by AP20187, which is consistent with previous reports showing the inability of this drug dimerization to cross the blood-brain barrier [@bb0050; @bb0140].

To understand the role of microglia/macrophages in glioma development, we targeted this population by administering for five consecutive days (1-5 days or 6-10 days) after cell implantation the B/B homodimerizer drug AP20187 to mice bearing GL261 intracranial tumors (Figure W4*A*). As mentioned previously, AP20187 induces Fas-mediated apoptosis through activation of the caspase-8 pathway in myeloid lineage cells. The day after treatment was completed (day 6 for group A and day 11 for group B), brains were analyzed for GFP^+^ cells. In tumor-containing hemispheres, the GFP^+^ cells were forcefully depleted (Figure W4*B*). The presence of GFP^+^ cells in the contralateral, non--tumor-containing hemisphere was not affected by the treatment (data not shown). Our data suggested that normal microglia is not targeted by AP20187, which is consistent with previous reports showing the inability of this drug dimerization to cross the blood-brain barrier [@bb0050; @bb0140].

To analyze the long-term impact of pharmacological targeting of the macrophage/microglia population in glioma tumors, we allowed for full glioma development in both group A and group B of the experiment ([Figure 4](#f0040){ref-type="fig"}*A*). Control animals were sacrificed between 16 and 20 days after cell implantation, when signs of disease burden were evident. Although AP20187-treated animals did not show signs compatible with glioma progression, we decided, on this time period, to have a more accurate comparison of tumor growth and analysis of the macrophage population. Analysis of the brains of the AP20187-treated animals revealed fewer GFP^+^ cells within tumors. We found that early ablation of macrophage cells (1-5 days post-implantation) resulted in an approximately 50% reduction in the number of GFP^+^ cells in tumors (*P* \< .01 *vs* control), while postponed treatment (6-10 days post-implantation) diminished the accumulation of GFP^+^ cells in tumors by 65% (*P* \< .001 *vs* control; [Figure 4](#f0040){ref-type="fig"}, *B* and *C*). Moreover, we found significantly fewer microglia/macrophages infiltrating the tumor periphery (by \~ 60%) in both early and postponed myeloid cell ablation (control *vs* AP20187 on days 1-5, *P* \< .001; control *vs* AP20187 on days 6-10, *P* \< .01). Ablation had no notable effect on microglia in intact brain, including the contralateral hemisphere.

To determine the impact of the temporal ablation of microglia/macrophages on the reconstitution of the tumor-associated myeloid population phenotype, we used double immunofluorescence to analyze the M1 and M2 status of those cells. Confocal analysis of Arg1^+^ and GFP^+^ cells in control mice showed that both early (1-5 days) and postponed (6-10 days) injection of the dimerization agent AP20187 reduced the number of double positive, Arg1^+^GFP^+^ cells in the center and periphery of the tumor (*P* \< .01 and *P* \< .001, respectively; [Figure 5](#f0045){ref-type="fig"}*A*). These results suggested that the number of M2-like polarized cells in the reconstituted pool decreased.

We then analyzed the M1 polarization of the reconstituted pool by performing double immunofluorescence image for GFP and iNOS. As we expected, iNOS^+^ cells within the tumor of control-treated MAFIA mice were rarely detected and appeared to be randomly distributed. Interestingly, agglomerations of iNOS^+^GFP^+^ cells were observed in tumor central areas in mice in which myeloid cell ablation was performed ([Figure 5](#f0045){ref-type="fig"}*B*). Compared with mice treated with AP20187 on days 1 to 5 and days 6 to 10, the number of iNOS^+^GFP^+^ cells in control-treated mice was approximately seven-fold and two-fold higher, respectively.

The data obtained suggested an M2-to-M1 shift in the phenotype of the reconstituted myeloid population present in the glioma microenvironment of MAFIA mice. Specifically, the M2/M1 ratio on reconstitution decreased by nine-fold and three-fold in mice treated with AP20187 on days 1 to 5 and days 6 to 10, respectively ([Figure 5](#f0045){ref-type="fig"}*C*; *P* \< .0001 and *P* \< .01, respectively).

Taken together, our results suggested that ablation of the CSF-1R^+^ myeloid population substantially alters the relative M1 and M2 representation in the tumor microenvironment and, subsequently, the functionality of the macrophage/microglia population.

Myeloid Cell Ablation Strongly Impairs the Growth of Intracranial Glioma {#s0070}
------------------------------------------------------------------------

To further explore the effect of temporal ablation of the tumor-infiltrating myeloid cells (CSF-1R--GFP^+^ cells) on glioma growth, we analyzed the phenotype of the tumors of MAFIA mice treated with AP20187 and compared it with tumors in control-treated mice ([Figure 4](#f0040){ref-type="fig"}*A*). Tumor volume analysis revealed that microglia/macrophage-depleted mice had smaller tumors, approximately 50% in size, than those of vehicle-treated animals ([Figure 6](#f0050){ref-type="fig"}, *A*--*C*, control *vs* AP20187 on days 1-5d and on days 6-10; *P* \< .05 for both comparisons), suggesting that microglia/macrophage ablation resulted in decreased tumor growth. To further evaluate the impact of the decrease in microglia/macrophage cells on tumor proliferation, we measured the number of Ki67^+^ cells within tumors. This analysis revealed a decrease of approximately 50% in the mitotic index when AP20187 was started immediately after tumor implantation (days 1-5, *P* \< .05) or after 6 days (*P* = .0562; [Figure 6](#f0050){ref-type="fig"}*D*). Of note, AP20187 treatment (ranging 0.01 to 10 nM) did not affect GL261 glioma cells or genetically wild-type RAW 264.7 macrophages as assessed by an *in vitro* viability assay (data not shown), suggesting that the treatment did not affect unexpected target populations. In addition, temporary ablation of CSF-1R--GFP^+^ cells resulted in decreased microvascular density after both AP20187 treatment regimens (*P* \< .05; [Figure 6](#f0050){ref-type="fig"}*E*). Together, our results showed that temporal ablation of myeloid populations resulted in decrease of the tumor proliferative and angiogenic properties, affecting significantly tumor growth.

Discussion {#s0075}
==========

Here, we report that conditional and temporal ablation of the CSF-1R^+^ population affect the reconstituted glioma myeloid population. Specifically, such ablation results in an increased M1/M2 ratio that, in turn, was associated with decreased tumor mitotic index, angiogenesis, and growth. Furthermore, we validated the use of the MAFIA transgenic model for further preclinical studies of brain tumors.

We found that the kinetics of the GL261 intracranial glioma growth in this transgenic model were similar to those previously described for other models [@bb0145; @bb0150; @bb0155]. Of interest, we observed an initial adaptive phase characterized by small islets of tumor cells scattered around the injection site, with exponential tumor growth after day 10 after tumor cell implantation. Consistent with other studies [@bb0110; @bb0135; @bb0160], GL261 intracranial glioma was characterized by tumoral microglia/macrophage infiltration, which was easily identified in the MAFIA model as accumulation of easily GFP-trackable cells. Our study also provided evidence of an increased presence of a microglia/macrophage population, which underwent morphologic modifications in the tumoral area during the adaptive tumoral phase, suggestive of a shift from a resting to an active state.

To further study the tumor infiltrating microglia/macrophage population, we performed immunofluorescence analysis to discriminate between the classically activated M1 and the alternatively activated M2 microglia/macrophage phenotype [@bb0015; @bb0165; @bb0170]. Although glioma-infiltrating GFP^+^ microglia/macrophages were evident within 5 days after cell implantation, they did not express detectable levels of the M2 marker Arg1 [@bb0120; @bb0125; @bb0130] until late in the adaptation stage. Furthermore, the accumulation of Arg1^+^ cells increased over time to represent the largest GFP^+^ microglia/macrophage population within 14 days after cell implantation. However, GFP^+^ cells rarely colocalized with the M1 marker iNOS [@bb0120; @bb0125; @bb0130], which confirmed a predominant M2 phenotype or protumorigenic phenotype of the microglia/macrophages associated with the GL261 glioma model [@bb0160].

Our data showed that conditional temporal ablation of microglia/macrophages was successfully achieved using the MAFIA transgenic model. Other pharmacological ablation methodologies, such as clodronate liposomes, are less selective in that they deplete cells depending on their phagocytic properties, including subtypes of T cells, and might fail to target other cells of peripheral macrophage lineage that eventually would be recruited as TAMs [@bb0050; @bb0070; @bb0140]. Of note, in the MAFIA transgenic model, ablation of normal CSF-1R^+^ microglia in the contralateral, non--tumor-bearing hemisphere was not noted, probably because of the inability of the dimerization treatment to cross the intact blood-brain barrier [@bb0050; @bb0070; @bb0115; @bb0140].

Interestingly, we found that conditional ablation, although transient, significantly affected the number and phenotype of the reconstituted pool of tumor-associated myeloid cells, which reduced the presence of GFP^+^ cells in tumors by 40% to 80%. Furthermore, the infiltrating population switched the polarization status due to a decrease in the M2 population. The presence of M2-polarized microglia/macrophages positively correlates with malignancy in gliomas; therefore, modifying the landscape scenario toward a more M1-like phenotype may be a useful strategy for glioblastoma therapy. Our results are in line with other efforts to neutralize tumor-associated chronic inflammation, such as blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) or signal transducer and activator of transcription 3/6 (STAT3/6) pathway or inhibiting cytokine pathways that dictate the recruitment or immune cell function, such as CSF-1 or chemokine (C-C motif) ligand 2 (CCL2) [@bb0170; @bb0175].

The work presented here demonstrated that temporal ablation of the macrophage population is sufficient to achieve a significant anti-glioma effect. The role of M2-polarized macrophages in promoting angiogenesis, cell migration and invasion, and an immunosuppressive tumor environment might explain that the decrease in number of GFP^+^ cells and M2/M1 ratio in the reconstituted population resulted in a decrease in tumor growth, angiogenesis, and proliferation in the model here studied [@bb0015]. Importantly, the MAFIA transgenic model is designed to both detect and target cells that express CSF-1R. This offers an interesting parallelism with recent studies that showed the CSF-1R inhibitor, BLZ945, resulted in both decreased M2 macrophage markers and subsequent tumor growth in a proneural glioma model [@bb0180]. Similarly, studies in other types of cancers using a monoclonal antibody that inhibits CSF-1R activation, RG7155, resulted in preferential targeting of the M2-polarized populations [@bb0135] and a subsequent increase in CD8^+^ T cell population [@bb0175] and decrease in FoxP3^+^ T regulatory cells [@bb0135].

In conclusion, we demonstrated that temporal ablation of macrophages in the MAFIA model results in an M2-to-M1 shift in the reconstituted myeloid population, which decreased tumor proliferation, angiogenesis, and growth. In addition, the intracranial glioma MAFIA transgenic model is an interesting tool for examining the putative role of macrophages in therapy resistance and for modeling the effect of new drugs targeting macrophages, either as single agents or in combination with glioma-targeted therapies.

The following are the Supplementary data related to this article.Figure W1Analysis of sham-operated brains. (A) Scheme of the experiment. Intracerebral injections of phosphate-buffered saline were given 14 days after guided screw cannulation. Five or 10 days later, animals were sacrificed and brains were collected, fixed in formaldehyde, and embedded in paraffin. (B) Representative images of GFP staining of microglia/macrophages on sections from cerebral (ipsi) and contralateral (contra) hemispheres for comparison. Scale bar, 100 μm.Figure W2Characterization of the GFP^+^ myeloid--derived cells infiltrating GL261 glioma in MAFIA mice. (A) Representative confocal microscope images of GFP (green) and CSF-1R (red) staining of brain sections from the tumor center and normal parenchyma (*intact*). DAPI (blue) was used for nuclear staining. Scale bar, 20 μm. (B) Representative confocal microscopy images of double immunofluorescence analysis for expression of GFP (green) and Iba1 (red) and from the tumor center and contralateral hemisphere (*intact*) of GL261-bearing mice. DAPI (blue) was used for nuclear staining. Scale bar, 20 μm.Figure W3CSF-1R expression in M1- and M2-polarized macrophages *in vitro*. (A) Quantitative evaluation of *arg1* and *nos2* (*inos*) mRNA expression in M0-, M1-, and M2-polarized RAW 264.7 macrophages, as assessed by real-time PCR. Data represent mean ± SD from three independent experiments and expressed as folds of change expression compared to M0-unpolarized RAW 264.7 cells (equal to 1). ^⁎⁎⁎⁎^*P* \< .0001. (B) Quantification of the percentage of M1- and M2-polarized RAW 264.7 cells that expressed CSF-1R, as assessed by FACS. (Left panel) Representative histogram of CSF-1R expression on polarized macrophages. Gray filled histogram: Cells stained with IgG isotype control. Dashed line: M1-polarized RAW 264.7 cells. Solid line: M2-polarized RAW 264.7 cells. (Right panel) Quantitative analysis of CSF-1R expression on M1-polarized (black circle) and M2-polarized (black square) RAW 264.7 cells. Data are presented as mean ± SD. ^⁎^*P* \< .05.Figure W4Depletion of microglia/macrophages in GL261 glioma--bearing MAFIA model. (A) Scheme of the experiment. Briefly, MAFIA mice were subjected to guided screw cannulation. Fourteen days later, GL261 cells were implanted into the right caudate nucleus. AP20187 or vehicle was administered daily from days 1 to 5 (group A) or from days 6 to 10 (group B) of the experiment. Animals were sacrificed 24 hours after the last dose (day 6 for group A and day 11 for group B) of the experiment. (B) Representative confocal images of sections of brains of GL261-bearing mice after treatment with vehicle only (control) or with AP20187, which resulted in a dramatic decrease in GFP^+^ cells (green). DAPI (blue) was used for nuclear staining. Scale bar, 20 μm.
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![Kinetics of GL261 intracranial glioma growth in MAFIA transgenic mice. (A) Scheme of the experiment. Briefly, MAFIA mice underwent guided screw cannulation, and 14 days later, GL261 cells were implanted into the right caudate nucleus. Animals were sacrificed 5, 10, 14, or 19 days after cell implantation, and their brains were assessed for morphologic characteristics. (B) Representative images of H&E (left and middle columns) and Ki67 (right column) staining of GL261 intracranial glioma sections from mice sacrificed at the indicated time points after tumor cell implantation. Scale bar, 500 μm (whole-brain tissue) or 50 μm (insets).](gr1){#f0025}

![Microglia/macrophage accumulation in tumor-bearing hemisphere. (A) Representative images of GFP staining using fluorescent microscopy show the presence of microglia/macrophages in tumor-bearing hemispheres, analyzed at the indicated time points after GL261 cell implantation. Images of contralateral, non--tumor-bearing hemispheres are shown for comparison. Scale bar, 100 μm. Insets show detailed cellular morphology. Scale bar, 60 μm. (B) Representative confocal microscopy images of GFP staining from the center and periphery of tumors. Dashed line, approximate tumor (T)/normal brain (N) edge. Scale bar, 20 μm. (C) Quantification of GFP^+^ cells (× 400) present in the tumor area and in the tumor-normal brain edge area (periphery) on sections of brains from animals sacrificed on day 14 or 19 post-implantation. HPF, high-powered field. Data are presented as mean ± SD (*n* = 3 mice). ^⁎⁎⁎^*P* \< .001 and ^⁎^*P* \< .05.](gr2){#f0030}

![Phenotypic characterization of the glioma-associated microglia/macrophage population. (A) Representative confocal images of Arg1 (red) and GFP (green) staining in brain sections from GL261 glioma--bearing animals sacrificed on day 5, 10, or 14 post-implantation. (Inset) White arrows highlight the increase in the number of Arg1^+^/GFP^+^ cells and change in morphology over time. DAPI (blue) was used for cellular nuclear staining. Scale bar, 20 μm. (B) Quantification of Arg1^+^/GFP^+^ cells in the center and periphery of tumors from mice sacrificed on day 14 or 19. Data are presented as mean ± SD (*n* = 3 mice). (C) Representative confocal images of iNOS (red) and GFP (green fluorescence) staining of brains of tumor-bearing mice sacrificed at the indicated times. (Inset) White arrows highlight the rare iNOS^+^/GFP^+^ cells, which were observed only at day 14. DAPI (blue) was used for nuclear staining. Scale bar, 20 μm.](gr3){#f0035}

![Influence of conditional macrophage ablation on tumor-associated myeloid cell reconstitution. (A) Scheme of the experiment. Briefly, GL261 cells were implanted into the right caudate nucleus of MAFIA mice. AP20187 or vehicle was administered daily from days 1 to 5 (group A) or from days 6 to 10 (group B) of the experiment. Animals were sacrificed 16 to 21 days after cell implantation. (B) Tumor sections from vehicle- or AP20187-treated mice were stained for GFP expression. Representative images from the center (upper row) and periphery (lower row) of tumors were acquired using confocal microscopy. Dashed line, approximate tumor (T)/normal brain tissue (N) edge. DAPI was used as nuclear staining. Scale bar, 20 μm. (C) Number of GFP^+^ cells per HPF (× 400). Data are presented as mean ± SD (*n* = 3 mice). ^⁎⁎⁎^*P* \< .001, ^⁎⁎^*P* \< .01, and ^⁎^*P* \< .05.](gr4){#f0040}

![Modifications in the repopulation of M1/M2-polarized myeloid cells after macrophage ablation. (A) Representative images of double immunofluorescence analysis for the expression of Arg1 (red) and GFP (green) in GL261-derived tumors of vehicle- or AP20187-treated MAFIA mice. DAPI (blue) was used for nuclear staining. Curved dashed lines indicate the approximate tumor (T)/normal brain (N) edge. Scale bar, 20 μm. The graph shows the number of double positive Arg1^+^GFP^+^ cells per HPF (× 400; central and peripheral areas). Data are presented as mean ± SD (*n* = 3 mice). (B) Representative images of sections from tumor-bearing mice treated with vehicle solution or AP20187 that were stained for iNOS and GFP expression. (Insets) Arrows point to iNOS^+^GFP^+^ cells. Scale bar, 20 μm. Quantitative analysis of the number of double positive iNOS^+^GFP^+^ cells per HPF in GL261-derived intracranial tumors from control or AP20187-treated mice (central areas). Data are presented as mean ± SD (*n* = 3 mice). (C) Quantitative analysis of M1 ratio as the/M1 ratio as the number of double positive Arg1^+^GFP^+^ cells per HPF *versus* the number of double positive iNOS^+^GFP^+^ cells per HPF in GL261-derived intracranial tumors from control or AP20187-treated mice (central areas). ^⁎⁎⁎⁎^*P* \< .0001, ^⁎⁎⁎^*P* \< .001, ^⁎⁎^*P* \< .01, and ^⁎^*P* \< 0.05.](gr5){#f0045}

![Outcome of temporal macrophage ablation on tumor growth. Design of experiment is described in [Figure 4](#f0040){ref-type="fig"}*A*. (A) Macroscopic photos of whole brains and coronal sections. Numbers (1-8) represent individual tumor-bearing mice. (B) Tumor volume in control-treated and AP20187-treated mice (*n* = 6 mice in control-treated group and *n* = 3 mice in each AP20187-treated group). Data are presented as mean ± SD. ^⁎^*P* \< .05. (C) Representative H&E-stained sections from each experimental group. Scale bar, 500 μm. (D) Number of Ki67^+^ cells in tumors from control-treated and AP20187-treated MAFIA mice. (Left panel) Data are presented as mean ± SD of Ki67^+^ cells scored from three or four microscopic fields (× 200). ^⁎^*P* \< .05. (Right panel) Representative microscopic pictures showing distribution of Ki67^+^ cells (brown; nuclear staining) in both control- and AP20187 (days 1-5)-treated animals. Scale bar, 50 μm. (E) Quantification of microvessel density in tumors from control-treated and AP20187-treated MAFIA mice. (Left panel) Data are presented as mean ± SD of microvessel density scored from three or four microscopic fields (× 200). ^⁎^*P* \< .05. (Right panel) Representative microscopic pictures showing vascular structures (CD31^+^, red fluorescence) in both control- and AP20187 (days 1-5)-treated animals. DAPI (blue) was used for nuclear staining. Scale bar, 50 μm.](gr6){#f0050}
